This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided by
Similar Posts
Master Pharmaceuticals Group – 715800 – 09/09/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetFDA Public Meeting: BsUFA III Regulatory Science Program Interim Public Meeting – 09/18/2025
The U.S. Food and Drug Administration (FDA) is hosting a hybrid in-person/virtual meeting on September 18, 2025, to meet the BsUFA III Commitment to review the progress of the pilot program’s aims, or demonstration projects, and solicit input on future priorities.GDUFA III Reauthorization
Generic drug user fees make it possible for FDA and industry to continue to ensure that the American public has access to safe, effective and high-quality generic drugs. The implementation of the Generic Drug User Fee Amendments (GDUFA) encompasses a wide range of activities that fall within the scoEnviroServe Chemicals & Cleaners Ltd. – 674090 – 09/09/2024
CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/MisbrandedInfusion Pump Recall: Zyno Medical Removes Certain Z-800 Series Infusion Pumps due to Software Issue
Infusion pumps released with incorrect software can experience unexpected performance problems, including issues with essential functions and risk measures.Natco Pharma Limited – 672564 – 09/25/2025
CGMP/Finished Pharmaceuticals/Adulterated